Jones Trading Upgrades Beam Therapeutics Stock Rating to Buy

Beacon Therapeutics (NASDAQ:BEAM) saw a shift in its stock rating as analysts at Jones Trading upgraded it from a "hold" to a "buy" in a report published on Monday. The brokerage set a target price of $34.00 for the stock, indicating a potential upside of approximately 26.34% based on the company's previous closing price.

Other brokerage firms have also assessed Beam Therapeutics recently. For instance, Cantor Fitzgerald upgraded the company’s rating from "neutral" to "overweight" on January 29th. Scotiabank followed suit, raising their rating from "sector perform" to "sector outperform," with a newly established target price of $40.00. On February 26th, Royal Bank of Canada increased their target price for Beam shares from $24.00 to $26.00 while maintaining a "sector perform" rating. Additionally, Wedbush reaffirmed an "outperform" rating with a target price of $57.00 on the same day as Jones Trading's report. Sanford C. Bernstein also raised its rating from "hold" to "strong buy" earlier in January.

Currently, the consensus among analysts regarding Beam Therapeutics includes two with a hold rating, ten who are recommending a buy, and two who have given a strong buy rating. According to MarketBeat, the overall average rating stands at "buy," with a consensus target price of $50.82.

Performance Overview of Beam Therapeutics

During midday trading on Monday, shares of Beam Therapeutics experienced a decline of $1.57, bringing the stock price down to $26.91. The trading volume reached 6,619,456 shares, significantly outpacing the average volume of 1,179,997 shares. Over the past year, the stock's performance has been notable, with a 52-week low of $20.84 and a high of $38.37. The company holds a market capitalization of $2.25 billion, and its price-to-earnings ratio stands at -15.23, suggesting an ongoing phase of investment and development rather than profitability.

The company recently reported its earnings on February 25th, showing an earnings per share (EPS) of ($1.09), which was an improvement over the consensus estimate of ($1.25) by $0.16. The reported revenue for the quarter was $30 million, exceeding analyst predictions of $16.47 million. It's important to note that the revenue has seen a downturn of 90.5% compared to the same quarter the previous year when the firm reported an EPS of $1.73. For the current year, analysts project an average EPS of -4.57.

Insider Trading Activity

In recent months, there has been insider trading activity at Beam Therapeutics. On January 2nd, insider Christine Bellon sold 1,241 shares at an average price of $24.68, totaling $30,627.88, which led to a 1.19% decrease in her holdings. Subsequently, CEO John M. Evans sold 30,000 shares on January 30th at $26.75 each, amounting to $802,500.00, thus reducing his ownership by 3.20%. After these transactions, insiders own approximately 4.20% of the company's shares.

Institutional Investors' Moves

A significant majority of Beam Therapeutics’ shares are held by institutional investors, who have been making strategic adjustments to their portfolios. Notably, Farallon Capital Management LLC slightly increased its position by 0.4%, acquiring an additional 31,000 shares during the fourth quarter, thus holding a total of 8,239,123 shares. ARK Investment Management LLC expanded its stake by 8.2%, now owning 7,068,029 shares. Additionally, Sumitomo Mitsui Trust Group Inc. and Nikko Asset Management Americas Inc. both boosted their holdings by 11.4%, contributing to the company's strong institutional support.

Beam Therapeutics focuses on creating precision genetic medications for serious diseases, highlighting its potential for long-term growth as advancements in biotechnology continue. The several updates from analysts signal a positive outlook for investors considering the firm’s innovative contributions in the field.

Stocks, Investment, Upgrades